Atropine

Therapeutic indications

Atropine is indicated for:

Refraction

Irrespective of gender only Children (1 year - 12 years old) , Adolescents (12 years - 18 years old)

Atropine sulfate is an antimuscarinic agent used as a cycloplegic and mydriatic.

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Ophthalmic - 1 drop once

Iritis, uveitis

Irrespective of gender only Children (1 year - 12 years old) , Adolescents (12 years - 18 years old)

The eye drops are used in the treatment of iritis and uveitis to immobilise the iris and ciliary muscle and to prevent or break down adhesions.

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Ophthalmic - 1-3 drops in 1-3 divided doses

Irritable bowel syndrome

Irrespective of gender only Children (1 year - 12 years old) , Adolescents (12 years - 18 years old) Adults (18 years old or older)

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Oral - 0.6-1.2 mg once

Non ulcer dyspepsia

Irrespective of gender only Children (1 year - 12 years old) , Adolescents (12 years - 18 years old) Adults (18 years old or older)

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Oral - 0.6-1.2 mg once

Diverticular disease

Irrespective of gender only Children (1 year - 12 years old) , Adolescents (12 years - 18 years old) Adults (18 years old or older)

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Oral - 0.6-1.2 mg once

Prophylaxis of vagal autonomic bradycardia during anaesthesia, salivary and bronchial secretions reduction

Irrespective of gender only Adults (18 years old or older)

Atropine is used in anaesthesia, to reduce the risk of vagal inhibition of the heart and to reduce salivary and bronchial secretions.

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Intramuscular - 0.3-0.6 mg once

Treatment 2: Intravenous - 0.3-0.6 mg once

Treatment 3: Subcutaneous - 0.3-0.6 mg once

Reversal of neuromuscular blockade

Irrespective of gender only Adults (18 years old or older)

Atropine is used in conjunction with neostigmine which is used to reverse the effects of non-depolarising muscle relaxants.

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Intramuscular - 0.6-1.2 mg once

Refraction

Irrespective of gender only Adults (18 years old or older)

Atropine sulfate is an antimuscarinic agent used as a cycloplegic and mydriatic.

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Ophthalmic - 1-2 drop once

Iritis, uveitis

Irrespective of gender only Adults (18 years old or older)

The eye drops are used in the treatment of iritis and uveitis to immobilise the iris and ciliary muscle and to prevent or break down adhesions.

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Ophthalmic - 2-8 drops in 1-4 divided doses

Poisoning by organo-phosphorous compounds

Irrespective of gender only Adults (18 years old or older)

Atropine is used in the treatment of poisoning by certain cholinesterase inhibitors e.g. organo-phosphorous compounds.

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Intravenous - 1.2-2 mg once

Treatment 2: Intramuscular - 1.2-2 mg once

Cholinergic crisis

Irrespective of gender only Adults (18 years old or older)

Treatment of cholinergic crisis of myasthenia gravis.

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Intravenous - 0.4-2 mg once

Cardiopulmonary resuscitation

Irrespective of gender only Adults (18 years old or older)

During cardiopulmonary resuscitation to counteract excessive vagal tone on the heart.

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Intravenous - 0.2-0.5 mg once

Prophylaxis of vagal autonomic bradycardia during anaesthesia, salivary and bronchial secretions reduction

Irrespective of gender only Minors (0 - 18 years old)

Atropine is used in anaesthesia, to reduce the risk of vagal inhibition of the heart and to reduce salivary and bronchial secretions.

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Intramuscular - 10-20 ug/kg once

Treatment 2: Intravenous - 10-20 ug/kg once

Treatment 3: Subcutaneous - 10-20 ug/kg once

Poisoning by organo-phosphorous compounds

Irrespective of gender only Minors (0 - 18 years old)

Atropine is used in the treatment of poisoning by certain cholinesterase inhibitors e.g. organo-phosphorous compounds.

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Intravenous - 50 ug/kg once

Treatment 2: Intramuscular - 50 ug/kg once

Contraindications

Active ingredient Atropine is contraindicated in the following cases:

Prostatic hypertrophy

No gender/age discrimination

Narrow-angle glaucoma

No gender/age discrimination

Paralytic ileus, pyloric stenosis, toxic megacolon, severe ulcerative colitis, reflux oesophagitis

No gender/age discrimination

Thyrotoxicosis

No gender/age discrimination

Myasthenia gravis

No gender/age discrimination

Myasthenia gravis (except when given with an anticholinesterase). No absolute contraindication to atropine in Advanced Cardiovascular Life Support (ACLS) or severe bradycardia.

< Previous: Overview

Precautions: Next >

Atropine

Therapeutic indications

Refraction

Treatment 1: Ophthalmic - 1 drop once

Iritis, uveitis

Treatment 1: Ophthalmic - 1-3 drops in 1-3 divided doses

Irritable bowel syndrome

Treatment 1: Oral - 0.6-1.2 mg once

Non ulcer dyspepsia

Treatment 1: Oral - 0.6-1.2 mg once

Diverticular disease

Treatment 1: Oral - 0.6-1.2 mg once

Prophylaxis of vagal autonomic bradycardia during anaesthesia, salivary and bronchial secretions reduction

Treatment 1: Intramuscular - 0.3-0.6 mg once

Treatment 2: Intravenous - 0.3-0.6 mg once

Treatment 3: Subcutaneous - 0.3-0.6 mg once

Reversal of neuromuscular blockade

Treatment 1: Intramuscular - 0.6-1.2 mg once

Refraction

Treatment 1: Ophthalmic - 1-2 drop once

Iritis, uveitis

Treatment 1: Ophthalmic - 2-8 drops in 1-4 divided doses

Poisoning by organo-phosphorous compounds

Treatment 1: Intravenous - 1.2-2 mg once

Treatment 2: Intramuscular - 1.2-2 mg once

Cholinergic crisis

Treatment 1: Intravenous - 0.4-2 mg once

Cardiopulmonary resuscitation

Treatment 1: Intravenous - 0.2-0.5 mg once

Prophylaxis of vagal autonomic bradycardia during anaesthesia, salivary and bronchial secretions reduction

Treatment 1: Intramuscular - 10-20 ug/kg once

Treatment 2: Intravenous - 10-20 ug/kg once

Treatment 3: Subcutaneous - 10-20 ug/kg once

Poisoning by organo-phosphorous compounds

Treatment 1: Intravenous - 50 ug/kg once

Treatment 2: Intramuscular - 50 ug/kg once

Contraindications

Prostatic hypertrophy

Narrow-angle glaucoma

Paralytic ileus, pyloric stenosis, toxic megacolon, severe ulcerative colitis, reflux oesophagitis

Thyrotoxicosis

Myasthenia gravis

Medication Recommendation

Related Medicines